Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 355

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 355
---
41,128

b)Revenue recognition related to IPH5201 AstraZeneca collaboration and option agreement

Revenue related to IPH5201 for the year ended December 31, 2024 is nil 4,677 5.0 4.7 2,060 1,165

c)Revenue recognition related to collaboration and license agreement signed with Sanofi in 2016

Revenues under the collaboration and license agreement signed with Sanofi in 2016 amounted to € 4,000 2,000 4,000

F-75

of € 3.0 2.0 4

d) Revenue recognition related to Sanofi research collaboration and licensing agreement (2022)

On January 25, 2023, the Company announced the expiration of the waiting period under theHart-Scott-Rodino(HSR)Antitrust Improvements Act of 1976 and the effectiveness of the licensing agreement as of January 24, 2023. Consequently, under the terms of such agreement, the Company received an upfront payment of € 25,000 18,500 1,500 5,000 two one two 15,000 13,300 1,700 31,800 18,500 13,300

Income from research work is recognized in the income statement using the percentage-of-completion method.

Following Sanofi's announcement in October 2024 that it would return the rights to the second option to terminate the research collaboration, revenue of 1,700 400

Change in deferred revenue relating to the 2022 research collaboration and licensing agreement :

  As of December 31, 2022             —             
 ────────────────────────────────────────────────────
  Additions                                  8,200  
  Deductions                   ( 2,874)             
  As of December 31, 2023                    5,327  
  Additions                           —             
  Deductions                   ( 2,101)             
  As of December 31, 2024         3,226             

F-76

e) Revenue recognition related to Takeda licensing agreement (2023)

On April 3, 2023, the Company announced that it has entered into an exclusive license agreement with Takeda under which Innate granted Takeda exclusive worldwide rights to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies against an undisclosed target, with a primary focus